Peter Borchmann

20.7k total citations · 1 hit paper
305 papers, 7.1k citations indexed

About

Peter Borchmann is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter Borchmann has authored 305 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 240 papers in Pathology and Forensic Medicine, 134 papers in Oncology and 107 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter Borchmann's work include Lymphoma Diagnosis and Treatment (240 papers), Lung Cancer Treatments and Mutations (104 papers) and CAR-T cell therapy research (51 papers). Peter Borchmann is often cited by papers focused on Lymphoma Diagnosis and Treatment (240 papers), Lung Cancer Treatments and Mutations (104 papers) and CAR-T cell therapy research (51 papers). Peter Borchmann collaborates with scholars based in Germany, United States and Switzerland. Peter Borchmann's co-authors include Andreas Engert, Volker Diehl, Michael Fuchs, Bastian von Tresckow, Dennis A. Eichenauer, Boris Böll, Hinrich P. Hansen, Elke Pogge von Strandmann, Roland Schnell and Stephanie Sasse and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Peter Borchmann

278 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

2012 485 citations Bertrand Coiffier, Barbara Pro et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Peter Borchmann

Since Specialization

Citations

This map shows the geographic impact of Peter Borchmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Borchmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Borchmann more than expected).

Fields of papers citing papers by Peter Borchmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Borchmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Borchmann. The network helps show where Peter Borchmann may publish in the future.

Co-authorship network of co-authors of Peter Borchmann

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Borchmann. A scholar is included among the top collaborators of Peter Borchmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Borchmann. Peter Borchmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma 2025 ·Haematologica ·Julia Wendler, Richard Lewis, (unknown), (unknown), (unknown), Elke Valk, Peter Borchmann, Jan‐Michel Heger, Gerald Illerhaus, Elisabeth Schorb	0
2	Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study 2025 ·JMIR Research Protocols ·(unknown), Ullrich Bethe, Peter Borchmann, Veronica Di Cristanziano, Lutz Gieselmann, (unknown), Martin Hellmich, (unknown), (unknown), (unknown), Juergen Prattes, Christof Scheid, Rosanne Sprute, Gertrud Steger, Jannik Stemler, Sibylle C. Mellinghoff, Oliver A. Cornely	0
3	Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG–NLG phase II BVB trial 2025 ·HemaSphere ·Alexander Fosså, Daniel Molin, Paul J. Bröckelmann, (unknown), Ulf Schnetzke, Johan Linderoth, Peter Kamper, Sirpa Leppä, Julia Meißner, (unknown), (unknown), Michael Fuchs, Peter Borchmann, Boris Böll	1
4	Long‐term remission in a patient with relapsed Richter's transformation treated with CD19‐directed chimeric antigen‐receptor T‐cells after allogeneic stem cell transplantation 2024 ·European Journal Of Haematology ·Nadine Kutsch, Philipp Gödel, Conrad‐Amadeus Voltin, Michael Hallek, Christof Scheid, Peter Borchmann, Udo Holtick	1
5	Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial 2024 ·Blood ·Paul J. Bröckelmann, Boris Böll, Daniël G. M. Molin, (unknown), Sirpa Leppä, Julia Meißner, Peter Kamper, Martin Hutchings, Jacob Haaber Christensen, Ulf Schnetzke, (unknown), Dennis A. Eichenauer, Bastian von Tresckow, (unknown), Peter Borchmann, Alexander Fosså	0
6	Noninvasive minimal residual disease assessment in relapsed/refractory large B‐cell lymphoma using digital droplet PCR 2024 ·European Journal Of Haematology ·Jan‐Michel Heger, (unknown), (unknown), (unknown), Jonathan M. Weiss, (unknown), Christian Becker, Kerstin Becker, Philipp Gödel, (unknown), Jörn Meinel, (unknown), Florian Simon, Hans Christian Reinhardt, Peter Borchmann, Sven Borchmann, Hyatt Balke‐Want, Gero Knittel, Bastian von Tresckow	5
7	Humoral immune response as an indicator for protection against Covid‐19 after anti‐SARS‐COV2‐booster vaccination in hematological and oncological patients 2024 ·International Journal of Cancer ·(unknown), Nathalie Bauer, (unknown), (unknown), (unknown), (unknown), Hassan Jomaa, (unknown), Peter Borchmann, (unknown), (unknown)	0
8	Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma—An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group 2024 ·International Journal of Radiation OncologyBiologyPhysics ·Johannes Rosenbrock, (unknown), Michael Oertel, Eren Celik, (unknown), Jiaqi Fan, Dennis A. Eichenauer, Paul J. Bröckelmann, Bastian von Tresckow, Carsten Kobe, Markus Dietlein, Michael Fuchs, Peter Borchmann, Hans Theodor Eich, Christian Baues	1
9	Estimation of Mediastinal Toxicities after Radiotherapy for Hodgkin Lymphoma—A Normal Tissue Complication Analysis of the HD16/17 Trial by the German Hodgkin Study Group 2024 ·Cancers ·Michael Oertel, (unknown), (unknown), (unknown), Michael Fuchs, Uwe Haverkamp, Peter Borchmann, Hans Theodor Eich	1
10	Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis 2024 ·Blood Advances ·(unknown), (unknown), Alex F. Herrera, Pier Luigi Zinzani, Ann S. LaCasce, Peter D. Cole, Craig H. Moskowitz, Ramón García‐Sánz, Michael Fuchs, Horst Müller, Peter Borchmann, Armando Santoro, Heiko Schöder, Josée M. Zijlstra, Barbara A. Hutten, Alison J. Moskowitz, Marie José Kersten	3
11	T-cell diversity and exclusion of blood-derived T-cells in the tumor microenvironment of classical Hodgkin Lymphoma 2024 ·Leukemia ·Nicole Seifert, Sarah Reinke, (unknown), (unknown), Julia Richter, (unknown), Hans Schlößer, Michaela Kotrová, Monika Brüggemann, Peter Borchmann, Paul J. Bröckelmann, Michael Altenbuchinger, Wolfram Klapper	1
12	Fertility and Gonadal Function after First-Line Treatment with Nivolumab-AVD in Hodgkin Lymphoma Patients: An Analysis from the Phase II GHSG Nivahl Trial 2023 ·Blood ·Paul J. Bröckelmann, (unknown), Peter Herhaus, Julia Meißner, Karolin Trautmann‐Grill, Horst Müller, Michael Fuchs, Bastian von Tresckow, Peter Borchmann, Andreas Engert, Karolin Behringer	0
13	PET/CT Reconstruction and Its Impact on [Measures of] Metabolic Tumor Volume 2023 ·Academic Radiology ·(unknown), (unknown), (unknown), Conrad‐Amadeus Voltin, Michael Fuchs, Peter Borchmann, Markus Dietlein, Carsten Kobe, (unknown)	4
14	Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma 2022 ·Clinical Lymphoma Myeloma & Leukemia ·Dominic Kaddu‐Mulindwa, Philipp Gödel, Nadine Kutsch, Jan‐Michel Heger, Christof Scheid, Peter Borchmann, Udo Holtick, Gerhard Held, Lorenz Thurner, Moritz Bewarder, (unknown), (unknown)	1
15	The interplay between cancer-related fatigue and functional health in Hodgkin lymphoma survivors. 2020 ·Health Psychology ·(unknown), Horst Müller, Helen Goergen, Stefanie Kreissl, Peter Borchmann, Axel Mayer	3
16	Consolidating Involved Field Radiotherapy Prevents Early and Local Recurrences in Early Stage Hodgkin Lymphoma 2019 ·International Journal of Radiation OncologyBiologyPhysics ·Christian Baues, Helen Goergen, Michael Fuchs, Carsten Kobe, Markus Dietlein, Johannes Rosenbrock, (unknown), Hans‐Theodor Eich, (unknown), R. Semrau, Peter Borchmann, Andreas Engert, Simone Marnitz	2
17	B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG) 2018 ·Kölner Universitäts PublikationsServer (Universität zu Köln) ·(unknown), Alexander Fosså, Helen Goergen, Peter Kamper, Sirpa Leppä, Daniel Molin, Julia Meißner, Erika Ritter, Jacob Haaber Christensen, Martin Hutchings, Martin Fuchs, Andreas Engert, Peter Borchmann, (unknown)	0
18	Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience 2012 ·Blood ·Achim Rothe, Stephanie Sasse, Helen Goergen, Dennis A. Eichenauer, Andreas Lohri, Ulrich Jäger, Christopher Bangard, Boris Böll, (unknown), Sebastian Theurich, Peter Borchmann, Andreas Engert	60
19	Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy breakdown → 2012 ·Journal of Clinical Oncology ·Bertrand Coiffier, Barbara Pro, H. Miles Prince, Francine M. Foss, Lubomir Sokol, Matthew Greenwood, Dolores Caballero, Peter Borchmann, Franck Morschhauser, Martin Wilhelm, Lauren Pinter‐Brown, Swaminathan P. Iyer, Andrei R. Shustov, Jean Nichols, Susan Carroll, John Balser, Barbara Balser, Sarah McCue Horwitz	485
20	Depletion of Cellular Cholesterol and Lipid Rafts Increases Shedding of CD30 2004 ·The Journal of Immunology ·Bastian von Tresckow, Karl‐Josef Kallen, Elke Pogge von Strandmann, Peter Borchmann, Hans Lange, Andreas Engert, Hinrich P. Hansen	93

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact